RBC Capital on Pliant Therapeutics (PLRX): 'we believe there was nothing concerning emerging from the call '
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to RBC Capital on Pliant Therapeutics (PLRX): 'we believe there was nothing concerning emerging from the call '
July 10, 2022 6:11 PM EDT
PLN-74809 demonstrated a dose-dependent treatment effect on FVC and QLF versus placebo over 12 weeks of treatment
PLN-74809 treatment effect was observed on top of standard of care therapy and as monotherapy
PLN-74809 was well tolerated over 12 weeks of treatment with no drug related SAEs and no treatment discontinuations due to adverse events
Company to host webcast and conference call tomorrow, Monday July 11 at 8:00 a.m. ET
SOUTH SAN FRANCISCO, Calif., July 10, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX),... More
July 10, 2022 6:10 PM EDT
PLN-74809 demonstrated a dose-dependent treatment effect on FVC and QLF versus placebo over 12 weeks of treatment
PLN-74809 treatment effect was observed on top of standard of care therapy and as monotherapy
PLN-74809 was well tolerated over 12 weeks of treatment with no drug related SAEs and no treatment discontinuations due to adverse events
Company to host webcast and conference call tomorrow, Monday July 11 at 8:00 a.m. ET
SOUTH SAN FRANCISCO, Calif., July 10, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today... More
